DexCom boosts 2023 revenue guidance on Q2 results
JHVEPhoto

DexCom (NASDAQ:DXCM) has upped its 2023 revenue guidance following strong Q2 financial results.
The continuous glucose monitor maker now sees 2023 revenue of $3.5B-$3.55B. Consensus is $3.5B.
DexCom also increased its non-GAAP gross profit margin and operating margin, as well as adjusted EBITDA margin estimates for the year.

In the quarter, net income increased ~128% to $115.9M ($0.28 per share diluted vs. $0.12). The company beat on the top and bottom lines.
DexCom (DXCM) ended the quarter with cash, cash equivalents, and marketable securities of ~$3.6B, a 48% increase from Dec. 31, 2022.

 More on DexCom

DexCom: Fantastic Growth But A High Premium To Pay Right Now
DexCom: 120 Times Free Cash Flow Is Still Unreasonable
DexCom: Growth Should Accelerate From Here